


1855.1052-029 Docket No.:

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al. Inventors:










1855.1052-029 Docket No.:


Title: Humanized Anti-CCR2 Antibodies... Gregory J. LaRosa, et al.


Inventors:

































Docket No.: 1855.1052-029 Title: Humanized Anti-CCR2 Antibodies... Inventors: Gregory J. LaRosa, et al. **LLUORESCENCE** FORWARD SCATTER MONOCYTES **DATA.001** PBS₁₀₃ **L**LUORESCENCE FORWARD SCATTER— GRANULOCYTES FIG. 2B DATA.001 PBS LLUORESCENCE FORWARD SCATTER— LYMPHOCYTES **DATA.001** FSC-H


SSC-H

PBS

Best available CCPY



Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...





1D9 10³ FL1-H


101

THE MAN AND ECON

Docket No.: 1855.1052-029 Title: Humanized Anti-CCR2 Antibodies... Inventors: Gregory J. LaRosa, et al. LLUORESCENCE FORWARD SCATTER— MONOCYTES FIG. 2L DATA.004 FSC-H 100₽ FL1-H 10 **LLUORESCENCE** FORWARD SCATTER— GRANULOCYTES FIG. 2K DATA.004 FSC-H 8G2 103 🚽 102 101 FL1-H LLUORESCENCE FORWARD SCATTER— LYMPHOCYTES FIG. 2J DATA.004 FSC-H 8G2 103 101 FL1-H










Title: Humanized Anti-CCR2 Antibodies...

Inventors:

Gregory J. LaRosa, et al.










1855.1052-029 Docket No.:

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al. Inventors:








DECT WALL TO BE COM


1.9284 ۸N Υ Ζ 2.6422 Error 0.15131 0.0006252 1C6 (anti CXCR3) 109 (µg/mL) ID9 (anti CCR2b) 1.0185 105.63 11.518 0.9948 Value 280.01 0.0037891 Bmax chisq Bmin \simeq 1050 \equiv




		JR2)	Error	0.0055353	0.60845	52.391	80.877	NA	NA	M Z		
Control IgG2a	1D9 (anti-CCR2)	1D9 (anti-CCR2)	Value	0.040086	2.0501	2762.3	541.62	2.9726e+05	0.99056	0.04µg/mL ≈ 0.2nM		
⊗	9			1050	H	Bmax	Bmin	Chisq	œ	0.0		
	•						·	- 63		- Ol		i.
	•							9		- 1		FIG. 5
	•	•		, .		, ·	,	J	- - - - - -	- l.O	body (µg/mL)	
	•								- - - - -	- 10.0	Antibody	
	•								-	- 100.0	1	
200	0000		2500	2000	, , , , , , , , , , , , , , , , , , ,		1000	500]	C	- 1000.0	,	
Ŋ	י כ י		•		noe] [-	d DI	Λ				

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.





Title: Humanized Anti-CCR2 Antibodies... Gregory J. LaRosa, et al. Inventors:

DVVMTQTPLT LSVTVGHPAS ISCKSSQSLL DSDGKTFLNW LLQRPGQSPK 1

51 RLIYLVSKLD SGVPDRFTGS GSGTDFTLKI SRVEAEDLGV YYCWQGTHFP

101 YTFGGGTKLE IK

Figure 7

Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

- EVQLVESGGG LVQPKGSLKL SCAASGFSFN AYAMNWVRQA PGKGLEWVAR
- 51 IRTKNNNYAT YYADSVKDRY TISRDDSESM LFLQMNNLKT EDTAMYYCVT
- 101 **FYGNGV**WGTG TTVTVSS

Figure 8

Title: Humanized Anti-CCR2 Antibodies... Inventors: Gregory J. LaRosa, et al.

Chothia Canonical Classes

L1 (16 amino acids) = Class 4

Key residues: 2(V), 25(SA), 29(L), 33(L), 71(F)

L2 (7 amino acids) = Class 1

Key residues: 48(IV), 51(AT), 52(ST), 64(G)

L3 (9 amino acids) = Class 1

Key residues: 90(QNH), 95(P)

Martin Canonical Classes

L1 (16 amino acids) = Class 4/16A

Key residues: 2(V), 4(ML), 23(C), 25(SSP), 26(SN),

27(Q), 29(LI), 30A(HL), 30B(S), 30C(NDS), 30D(G), 32(YS), 33(LF), 34(HEN), 35(W), 51(V), 71(F), 88(C),

90(Q), 92(TS), 93(H)

L2 (7 amino acids) = Class 1/7A

Key residues: 23(C)

L3 (9 amino acids) = Class 1/9A

Key residues: 2(IVL), 3(VQLE), 4(ML),

28(SNDTE), 30(DYLVISNFGHT), 31(SNTKG), 32(FYNAHSR), 33(MLVIF), 88(C), 89(QSGFL), 90(QNH), 91(NFGSRDHTYV),

92(NYWTSRQHAD), 93(ENGHTSRAQHAD),

94(DYTVLHNNIWPS), 95(P), 96(PLYRIWF), 97(T), **98(F**)

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

Chothia Canonical Classes

H1 (5 amino acids) = Class 1

Key residues: 24(AVG), 26(G), 27(FY)

H2 (19 amino acids) = Class 4

Key residues: 54(S), 55(Y), 71(R)

Martin Canonical Classes

H1 (5 amino acids) = Class 1/10A

Key residues: 2(VIG), 4(LG), 20(LIMV), 22(C),

24(TAGVS), 26(G), 29(IFLS), 32(IHYFTNCED), 33(AWGTLV), 34(IVMW), 35(HENQSYT), 36(W),

48(IMLV), 51(LIVTSN),

69(ILFMV), 78(ALVYF), 80(LM),

90(YF), 92(C), 94(RKGSNH),

102(YHVISDG).

H2 (19 amino acids) = Class ?/12B

Key residues: 47(W), 50(RQ), 51(I), 59(Y), 69(I),

71(R), 78(LV)

Figure 10

CDRs	=======[3=======
Kabat Numbers	$\frac{1}{123456789012345678901234567890123456789012345678901234567890123456789012345678901234567890123458789012345687$
$1D9 V_{K}$	DVVMTQTPLTLSVTVGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEI-K
HF-21/28 V _K	$\dots S.S.P.L.Q.\dots R.\dots VH. \dots VH. \dots R.\dots R.\dots R.\dots R.\dots R.\dots R.\dots S.\dots \dots S.\dots \dots S.\dots \dots V.\dots M.\dots W. F.\dots QR.\dots$
1D9RK _A V _K	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDS-DGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEI-K
$1D9RK_B$ V_K	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEI-K
$1D9RK_C$ V_K	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGGGTRLEI-K
$ID9RK_D V_K$	DVVMTQSPLSLPVTLGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGGGTRLEI-K
Key	
$1D9 V_K$	Mouse 1D9 V_{K} region
HF-21/28 V_K	Chosen human framework acceptor V _K region sequence with mismatches to the 1D9 V _K region highlighted.
1D9RK _A V _K	CDR grafted 1D9 V _K region, with no back mutations but with the added human lysine residue at position 107 (i.e. 107K).
$1D9RK_BV_K$	CDR grafted 1D9 V_K region, with back mutations at F36L and Q37L, and the additional 107K insertion.
$1D9RK_CV_K$	CDR grafted 1D9 V_K region, with back mutations at F36L, Q37L and Q100G, and the additional 107K insertion.
$1D9RK_D V_K$	CDR grafted 1D9 V _K region, with back mutations at F36L, Q37L, Q100G and Q17H, and the additional 107K insertion.

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Kigure II

n	1 1 234567890123	WGTGTTVTVSS	RQL	GVWGQGTLVTVSS	VWGQGTLVTVSS	VWGQGTLVTVSS	GVWGQGTLVTVSS	
=====H3======	1 1 1 4 5 0 0 1 890123456789012ABC34567890123456789012ABC345678901234567890ABC-IJK1234567890123	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTFYGNGVWGTGTTVTVSS		:TTFYGNG	1D9RH _b V _H EVQLVESGGGLVKPGGSLRLSCAASGFSFNAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS	1D9RH _c V _h EVQLVESGGGLVKPGGSLRLSCAASGF SFN AYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDR Y TISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS	VTFYGNG	
	9 12ABC3456789012	.QMNNLKTEDTAMYYO		QMNSLKTEDTAVYYC	QMNSLKTEDTAVYY	QMNSLKTEDTAVYY	QMNSLKTEDTAVYY	
	7 678901234567890	RYTISRDDSESMLFI	GKS.TDGGT.DAPG.FKNT.YSVT.DSLPPH	RFTISRDDSKNTLYI	RFTISRDDSKNTLYI	RYTISRDDSKNTLYI	RYTISRDDSKNTLYI	
H2	6 BC3456789012345	KNNNYATYYADSVKE	.TDGGT.DAPG	KNNNYATYYADSVKE	KNNNYATYYADSVKL	KNNNYATYYADSVKI	KNNNYATYYADSVKE	
11 11 11	4 90123456789012A	DAPGKGLEWVARIR T) PGKGLEWVGRIRT	JAPGKGLEWVGRIR I	DAPGKGLEWVARIRI	DAPGKGLEWVARIR I	
H]===	1 1234567890123456789012345AB678	SGFSFNAYAMNWVR(T.SNAW.S	1D9RH, V" EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGN	SGFSFNAYAMNWVR	SGF SFN AYAMNWVR(1D9RH _D V _H EVQLVESGGGLVKPGGSLRLSCAASGF SFN AYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDR Y TISRDDSKNTLYLQMNSLKTEDTAVYYC VT FYGN	
	2 123456789012345	JVQPKGSLKLSCAAS	4B4'CL VHK.GRT.SNAW.S	LVKPGGSLRLSCAAS	LVKPGGSLRLSCAAS	LVKPGGSLRLSCAAS	LVKPGGSLRLSCAAS	
		EVQLVESGGG	V _H	V _H EVQLVESGGG	V _H EVQLVESGGG.	V _H EVQLVESGGG	V _H EVQLVESGGG	
CDRs	Kabat Numbers	109	4B4'CL	1D9RH _A	109КН _в	1D9RH _c	109кн _р	

Key

1D9 V_H Mouse 1D9 V_H region.

Chosen human framework acceptor V_H region sequence with mismatches to the 1D9 V_H region highlighted. 4B4'CL $V_{\rm H}$

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

1D9RH_A V_H CDR grafted 1D9 V_H region, with no back mutations.

1D9RH_B V_H CDR grafted 1D9 V_H region, with back mutations at T28S and S30N.

CDR grafted 1D9 $V_{\rm H}$ region, with back mutations at T28S, S30N, G49A and F67Y. $1D9RH_{C}V_{H}$

CDR grafted 1D9 V_H region, with back mutations at T28S, S30N, G49A, F67Y and T93V. $1D9RH_D V_H$

Figure 12

D9 V _K	114	DVVMTQTPLTLSVTVGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFP
0/3	97	I. Q
0/1	94	
0/2	82	XLHSI.QY. NYV.PYSXPX.M.D
-IB	16	S.P.SL.DQRVH. N.N.Y.Y.Y.X.
-1C	75	$\dots \dots $
-1A/K5.1/K5.1	75	S
-1C/V1A5/K1A5	74	LS.P.SL.DQRIVH. N.N.Y.E.YKLKNRFSSFS.V.
18.1	73	S
נדי	71	:
4A	89	.IAAFSNPL.TSRKH. S.N.Y.Y.FKQLYI.N.ASRVMLEY.
67/24	29	.I.I DE. SNP S. ESV R K YK Y F QL M. TRA S S E K V Q. LVEY.
4B	99	.IAAFSNPL.TS,.RKH. N.I.Y.Y.Y.KQLQM.N.ASSRVA.NLEL.

1D9 V _H	117	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMN	CAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTF
MRL-RF24BG	98	VWWRMTTT	S. SS
V(H)22.1	70	K.EGMVT.SN.W.S	S.EQL.SDHEG.FK.SVYRAGITG-
V11/pBV19B4	. 99	K	\dots PALGFN.A.G.T.E.SAG.FN.Q.I.YT.RAS.TAR-
Vh7183 (Vh69.1)	99	KK.GT.SS.T.S	S.E.RT.SSGGSYPG.FNAKNT.YSSSTR-
VH10-19	65	D.KK.GT.SS.T.S	T.E.RT.SSGGSYPG.FNAKNT.YSSSTR-
VHE4-psi	65	.L	T.E.RA.SDGSFI.XP.TG.FNAKNTSS.RYLR-
V(H)50.1	65	K	T.E.RY.SNGGGSP.TG.FNAKNT.YSRSAR-
V3	65	K	HRPPL.LN.A.G.I.E.SA.M.G.FN.Q.I.YT.SS.TARD
V1/pBV132	64	K	PRI.AS.N.A.D.T.E.SAG.FIVT.Q.I.YA.RAIAR-
VH283	64	MK.GT.SS.T.S	T.E.RT.SSGGGNPG.FNAKNN.YSS.RSLAR-
V(H)37.1	63	KK.GT.SS.G.S	T.E.RT.SGGGSYPG.FNAKNN.YSS.RSLAR-
V13	61	K.MGARET.TD.Y.	L.R.SPL.L.N.A.G.T.E.SAG.FN.QNI.YT.RA.AS.TAKD
V-H 441/V441	59	K.LGD.SR.W.S	IGE.NPDSSTIN.TP.LKFINAKNT.YSKVRSLAR-
68-5N	59	T.SS.G.S	T.D.RLT.NSGGSPG.FNAKNT.YSSSAR-
76-1BG/VH7183.9	58	T.SSS	NAKNT.YSS.RS
61-1P	58	T.SSFG.H	EY.SSGSSTIT.G.FNPKNTTS.RSAR-
57-1M/VH7183.12	58	SK.GT.SSS	NARNI.YSS.RS
V(H)55	26	K.LGND.SR.W.S	NAKNT.YSKVRS
VH7183.13	55	T.SS.T.S	T.E.RY.SNGGGSP.TG.FNAKNT.YSSSAR-

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Docket No.: 1855.1052-029

Title:	Humanized Anti-CCR2 Antibodies
_	

ritio.	Human	IIZCU ZIII	.1-(LLIC	,00
Invento	ors:	Gregory	J.	LaRosa,	et	al.

	susurusesleeceseeseesesseses seeceeerusesseeleese	ccccscscsccccccccscs s 1 1 8 9 0 234567890123456789012345ABCDEF67890123456A7
	123456789012345678901234567ABCDEF89012345678901234567890123456789012345678901234567890123456789012345ABCDEF67890123456AP v v	=====L3=======V
1D9 V _K 100	100.0 DVVMTQTPLTLSVTVGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFP	TLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEI-K
036521 90.4	4 .IQLSI.QY	D FPQ
~	$\dots LSSPL.Q.\dots.R.DVY. \dots YYQ.\dots.RKNR.\dots$	$\dots E \dots \dots V \dots M \dots M.$ $G \dots Q \dots V \dots$
RPMI6410 78.8	.8S.S.P.L.QRVYNYFQRK.NRS	
~	.8 V. S. S. P. L. Q R. L. V N. Y F QL. SR S	
¥ %	.1 $SS.PL.QRG.vy.$.D. $YFQRNK.NRNS.G$	
7,	.3SSP. L.QRVHN.YFQRNRNRS	
SpA2-08 77.	9 AEEL.S.S.P. L.QRL. D.YYQR.NK.NRSS	VMA.W.
7	.9LSSL.QR.T.I.VFN.YFQ.TH.RRNRS	
7	.9S.S.P. L.QRVFN.YFQRK.NRS.	S
7.	.7S.S.P.L.QRVHN.YFQRR.NRS	
7	.8 . ISP.QHY.Y.Y.Y.KP.QLENRFS	
ToP218 74	.8 .ISP.Q	VM.SIQL.R FP
7	.1 AEELSS.PL.QRVYN.YFQRK.NRS	
11.37 75.	.2SS.PL.QSTVYTIYFQRFKNRS	VAIM GQ
7	9 IS.PP.ERGN.YYKAQLTL.YRAS	QVM.RLEI.
one 51 74	.6 .IS.PL.QRRG.VHN.YFQRKNRSA	
7	.2 .I.LSS.PL.QRN.VYN.YFQRKNRS.S	TV.IMRW.

Amino Acid Sequence

rigure 15

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Name	e	ID Surface Core Kabat CDR	Core	Kabat CDR	FR	FR Surface	Core FR	FR Near CDR	Vernier	V _K	J Chain	Closest Human Germline Gene	Li LenL2 LenL3 Len L1 Cla	enL3 Le	n L1 Class	L2 Class	L3 Class
1D9 V _K	100.0) 30	82	32	82	22	09	33	41	100	41		16 7	6	4	-	_
036521 II.66	90.4 78.8	27 25	9 <i>L</i> 67	28	75	19	56 52	31	13	90	13	DPK19-A1+ DPK18-A17+	Same Same	e Same	Same	Same	Same
RPMI6410 ZM1-1	78.8		<i>29</i>	22	69	<u>& &</u>	52 52	30	13	92	12	DPK18-A17+ DPK18-A17+	Same Same Same Same	e Same	Same Same	Same Same	? Same
VL clone 54	78.1		99	21	89	18	52	30	13	79	12	DPK18-A17+				Same	Same
HF-21/28	79.3		99	21	89	<u>8</u>	52	30	13	78	12	DPK18-A17+	Same Same	e Same	Same	Same	Same
SpA2-08	77.9	24	65	21	89	18	51	30	13	11	12	DPK18-A17+			٠	Same	Same
II.30	77.9		65	21	89	18	51	30	12	11	12	DPK18-A17+	Same Same	e Same	Same	Same	Same
HUNVK	77.9		65	21	89	8	51	30	12	11	12	DPK18-A17+	Same Same	e Same	Same	Same	Same
0-81	75.7		65	21	89	18	51	30	12	11	12	DPK18-A17+	Same Same	le 10	Same	Same	ć
ToP309	74.8		64	20	89	18	51	29	12	9/	12	DPK12-A2+	Same Same	le 10	ċ	Same	خ
ToP218	74.8		64	20	89	18	51	29	12	9/	12	DPK12-A2+	Same Same	e 10	ç	Same	ć
SpA3-02	76.1		63	20	89	18	51	29	12	9/	12	DPK18-A17+	Same Same	e Same	<i>د</i> .	Same	Same
11.37	75.2		63	20	89	18	51	29	12	9/	12	DPK18-A17+	Same Same		Same	Same	Same
CUM	73.9		63	. 07	89	18	20	29	12	75	12	DPK36-Chr22 4	17 Same	e Same	m	Same	Same
VL clone	74.6		62	20	29	18	50	29	12	75	12	DPK18-A17+	Same Same	e Same	<i>د</i> .	Same	Same
11.20	75.2	23	62	20	<i>L</i> 9	18	50	29	12	75	12	DPK18-A17+	Same Same	e Same	<i>د</i> .	Same	Same

gure 17A

Name	A	${f constant}$
		1 1 2 3 4 5 6 7 8 9 0 0 1 1 1 2 3 4 5 1 1 8 9 0 0 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
ID9 V _H	100.0	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMN—WVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTFYGNGVWGTGTTVTVSS
030094	67.7	SGN.D.SAAAG.FNIAYSIVIRGSSMVRGVNG
N51P8	68.3	I.SD.Y.DAI.T.N.A.S.T.EAG.FMNS.SSIICVRTDCSSTRC F
IW2-91 H2-46	66.7	
039158	72.2	T.SGS.IHSVGH.N.PA.A.A.G.FKNIAYSVASGSYLK
038064	65.6	T.SSSSA.SGSGGSG.F
038062 32.B9	64.6 64.6	
038062	64.6	
034514	8.69	T.SSS
038066	65.3	SS.RAVBG.SGSGGSEG.FN.KNT.YS.RAVAND.YGSGRYFTYAT
035365	62.9	S.RAS.RASA.SG-SG.TG.FN.KNT.YS.RAVAKKP.DYGSGSY
Hb-5	69.2	GRRT.S
4012 VH Clone 39	04.0	
040094	62.5	I.SIGW.S
VH Clone 18	63.0	

Amino Acid Sequence

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Docket No.: 1855.1052-029

Title:	Humanized Anti-CCR2 Antibo	dies.
Invente	rs: Gregory J. LaRosa, et a	ıl.

I	nv	/eı	nto	ors	: :	
4						

Name ID	·	UB1-24 67.2 029764 64.5 IW2-105 64.5 UB1-17 65.0 VH Clone 41 66.1 4B4°CL 67.2 M26 65.0
ossgaggascoscoscoscosgaggaggascoscoscoscoscosgaggagascoscoscosgaggagascoscosgascoscoscoscoscosgascoscosgascosco	1 1 2 3 4 5 6 7 8 9 0 1 1 1 2 3 4 5 5 1 1 1 2 3 4 1 5 1 1 1 2345678901234567	Q.
၁၁ဧ၁၁ဧ၁၅၁၁၁	1 1 1JK1234567890123	XYYYYGMD Q

Amino Acid Sequence

Figure 17B

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

	ln	ven	toı	s:		(Jre	go	ГУ	J. 1	Jai	XO.	su,
H2 Class	4	Same	Same	Same	Same				3				
H1 Class		Same	ċ	Same	Same				Same				
H3 Size	9	16	15	15	15				19				
H2 Size	19	Same	Same	Same	Same				17				
H1 Size	5	Same	Same	Same	Same				Same				
Vernier V _H J Chain Closest Human Germline Gene		DP-29-122+	DP-29-122+	DP-29-122+	DP-29-122+	DP-29-122+	VH26Rabbitts+						
J Chain	17	13	13	12	12	12	12	12	12	12	12	12	12
>	001	75	75	75	75	74	74	73	72	72	72	71	71
Vernier	16	12	12	12	12	12	Ξ	Ξ	11	11	11	11	=
FR Near CDR	30	26	25	25	25	25	25	25	25	25	25	25	25
Core	92	57	57	99	99	99	99	99	99	99	99	55	55
FR Surface	21	17	91	16	16	15	15	15	15	15	15	15	15
FR	87	72	72	72	75	71	71	71	71	71	70	70	70
Kabat CDR	30	15	15	15	15	15	14	14	14	14	14	14	14
Core	84	<i>L</i> 9	99	65	9	64	64	63	63	63	63	63	63
Surface Core	29	19	18	18	18	17	17	17	17	17	17	16	16
All	117	98	98	85	84	83	82	82	82	82	81	81	81
a	100.0	1.19	68.3	67.5	2.99	72.2	9.59	64.6	64.6	64.6	8.69	65.3	62.9
Name	1D9 V _н	030094	N51P8	IW2-91	H2-46	039158	038064	038062	32.B9	038062	034514	990860	035365

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Name	e	AII	All Surface Core	Core	Kabat CDR	FR	FR Surface	Core FR	FR Near CDR	Vernier	× H	J Chain	Closest Human Germline Gene	H11 Size	H2 Size	H3 Size	H1 Class	H2 Class	
Hb-5 4G12 VH clone	69.2 64.8 66.7	81 81 80	16 16 16	63	14 14 14	69 69	15	55 55 55	25 25 25	===	71 71 71	12 12 12	VH26Rabbitts+ VH26Rabbitts+ VH26Rabbitts+	Same	17	16	Same Same	m m	
040094 VH clone	62.5	80	16 16	63	14	69	14	55 55	25 25	==	17	12	LSG3.1 VH26Rabbitts+	Same	17	18	Same	n	
UB1-24 029764 IW2-105	67.2 64.5 64.5	80 80 80	16 16 16	63 63	13	69 69	1 1 1 1	55 55 55	25 25 25	===	17 17 17	12 12 12	DP-31-V39P+ VH26Rabbitts+ LSG3.1	Same Same	17 17 Same	10 15 13	Same Same Same		-
UB1-17 VH clone 41	65.0 66.1	80	16 16	63	. 13	69	14 14	55	25 25	= =	71	= =	LSG3.1 VH26Rabbitts+		Same 17	12	Same Same	ç. tü	
4B4°CL M26	67.2 65.0	80	16 16	62	13	89	4 4	55 55	25 25	==	17	ΞΞ	LSG3.1 LSG3.1	Same Same	Same Same	8 2 2	Same Same	٠٠ ٠٠	

Kabat	#	FR or CDR	Mouse 1D9 V _K	Mouse κ-II	Human к-II	Human Acceptor HF-21/28 (005056)	Surface or Core	1D9 RK _A	1D9 RK _B	Comment
1	1	FR1	D	D*	D		S	D	D	
2	2		v	V	I*		c	V	V	
3	3	 	v	v	V*		S	T v	V	
4	4		М	M	M		c	М	M	
5	5		T	T*	T		С	T	Т	
6	6		Q	Q*	Q		С	Q	Q	
7	7	1	T	T	Š	S	S	S	S	
8	8	 	P	P	P		с	P	P	
9	9	1	L	L	L	<u> </u>	s	L	L	
10	10	1	T	S	S	S	C	<u>s</u>	<u>s</u>	
11	11		L	L	L*		С	L	L	
12	12	1	S	P	P	P	С	P	P	
13	13		V	V*	V*		С	V	V	1
14	14		Т	S	T		С	T	T	
15	15		V	L	P	L	S	L	<u>L</u>	
16	16		G	G	G		С	G	G	
17	17		Н	D	E	Q	С	Q	Q	
18	18		P	Q	P		's	P	P	
19	19		Α	A	A		С	A	Α	
20	20		S	S*	S		С	S	S	
21	21		I	I*	I		С	I	Т	
22	22		S	S*	S*		С	S	S	
23	23	FR1	L	С	C		С	С	С	
24	24	CDR1	K	R	R	R	S	K	K	
25	25		S_	S*	S*		С	S	S	
26	26		S	S*	S		S	S	S	
27	27	 	Q	Q	Q		s	Q	Q	1
27A	28	 	S_	S	S	ļ	s	S	S	ļ
27B	29	 	L	L	L		С	L L	L	
27C	30		L	V	L	. V	S	L D	L D	
27D	31		Q	H S	H S	H	С	S	S	1
27E	32	 	S	3	X		S	-	-	
27F 28	33	1	D .	N	D		s	D	D	†
29	34	-	G	G*	G		c	G	G	1
30	35	++-	K	N	N	N	c	K	K	
31	36	 	T	T	N	11/	c	T	T	
32	37		L	Y*	Y	Y	c	F	F	<u> </u>
33	38	+ + -	L	L*	L		c	L	L	
34	39	CDR1	N	E	N		- c	N	N	
35	40	FR2	w	W	W		č	W	W	1
36	41	1.112	L	Y	Y	F	C	F	L	Δ1

Figure 19A

Docket No.:

Docket No.: 1855.1052-029
Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al.

Kabat	#	FR or CDR	Mouse 1D9 V _K	Mouse κ-II	Human K-II	Human Acceptor HF-21/28 (005056)	Surface or Core		D9 RK _A	1D9 RK _B	Comment
37	42		L	L -	L	Q	c		Q	L	Δ2
38	43		Q	Q*	Q		С		Q	D	
39	44		R	K	K		С		R	R	
40	45		P	P*	P		S		P	P	
41	46		G	G*	G		S		G	G	
42	47		Q	Q	Q	·	С		Q	Q	
43	48		S	S*	S		С		S	S	
44	49		P	P*	P		C		P	P	
45	50		K	K	Q	R	С		<u>R</u>	<u>R</u>	
46	51		R	L	L		С		R	R	
47	52		L	L*	L		С		L	F	
48	53		I	1*	I		С		I	I	
49	54	FR2	Y	Y	Y		С		Y	Y	
50	55	CDR2	L	K	L		С		L	L	
51	56		V	V	V	K	С		V	V	
52	57		S	S	S		С		S	S	
53	58		K	N	N		С		K	K	
54	59		L	R	R	N	С		L	L	
55	60		D	F	Α	R	С		D	D	i
56	61	CDR2	S	S*	S		S		S	S.	
57	62	FR3	G	G	G		S		G	G	
58	63		V	V	V		С		V	V	
59	64		P	P	P		С		P	P	
60	65		D	D*	D		S		D	D	
61	66		R	R	R		С		R	R	
62	67		F	F*	F		С		F	F	
63	68		Т	S	S	S	С		<u>s</u>	<u>S</u>	
64	69		G	G*	G		C	_	G	G	
65	70		S	S*	S		C	i_	S	S	
46	71		G	G*	G		С	_	G	G	
67	72		S	S*	S		S		S	S	
68	73		G	G*	G		С	\perp	G	G	
69	74		T	T*	T	ļ	С		I	T	ļ
70	75		D	D*	D		С	_	D	D	
71	76		F	F*	F	ļ. <u></u>	С		F	F	<u> </u>
72	77		T	T*	T	ļ	С	-	T	T	ļ
73	78		L	L	C		С	_ _	L	L	-
74	79	-	K	K	K	-	С		K	K	-
75	80	ļ	I	I	T	ļ	c		I	I	
76	81	ļ	S	S	S	 	c		S	S	-
77	82		R	R*	R	 	S		R	R	
78	83	<u> </u>	V	V	V	 	С	$-\!\!\!\!+\!\!\!\!\!-$	V	V	
79	84	 	E	E	E		S	- -	E	E	
80	85	 	A	A*	A	 	c	$-\!$	A	A E	
81	86	 	E	E*	E		S		E		ļ
82	87		D	D*	D	17	С		D	D V	+
83	88	1	L	L	V	V	С	1 == (1)	V		
84	89	+	G	G*	G	<u> </u>	c		G	G	
85	90	-	V	V	V	 	C		<u>V</u>	V Y	-}
86	91	-	Y	Y*	Y	<u> </u>	C				-
87 88	92	FR3	Y C	Y C	Y		C		Y C	Y C	

Figure 19B

Kabat	#	FR or CDR	Mouse 1D9 V _K	Mouse κ-II	Human κ-II	Human Acceptor HF-21/28 (005056)	Surface or Core	1D9 RK _A	1D9 RK _B	Comment
89	94	CDR3	w	F	– M		c	- w	w	
90	95		Q	Q*	Q	M	С	Q	Q	
91	96		G	G	A		С	G	G	
92	97		T	T	L		С	Т	T	
93	98		Н	Н	Q		С	Н	H	
94	99		F	V	х		S	F	F	
95	100		P	P*	P	W	С	F	P	
95A			-	P	R			<u> </u>	-	
95B			-	-	-			-	-	
95C			-	-	-			_	-	
95D			-	-	-			-	-	
95E			-	-						
95F			-		-				-	
96	101		Y	Y	х	-	С	Y	Y	
97	102	CDR3	T	T*	T	F	С	T	T	
98	103	FR4	F	F*	F	,	C	F	F	
99	104		G	G	G		С	G	G	
100	105		G	G	Q	Q	С	Q	<u>G</u>	
101	100		G	G	G		С	G	G	
102	106		T	T	T		. c	T	T	
103	107		K	K*	K	R	s	<u>R</u>	<u>R</u>	
104	108		L	L	V		С	L	Е	
105	109		Е	E	E		S	E	E	
106	110		I	I	I		S	I	I	
106A			-	-	-			-	-	
107	111	FR4	K	K*	K	-	s	K	K	

Figure 19C

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core	1D9 RH _A	1D9 RH _B	Comment
1	1	FRI	L	E*	E		S	E	F	
2	2	- 11(1	T V	V	T v		c	V	V	
3	3		Q	K*	1 0		s	' 0	Ö	
4	4		L	L*	L*		c	L	L	
5	5		V	E	V .		s	$\frac{1}{v}$	v	
6	6	1	L	E	L		c	E	E	
7	7	- .	S	S	S*		c	S	S	
8	8	1:	G	G	.G*		С	G	G	
9	9		G	G	G*		С	G	G	
10	10		G	G*	G		c	G	G	
11	11		L	L	L		S	L	L	
12	12		V	V*	V		c	V	V	
13	13		Q	Q	Q	K	S	<u>K</u>	K	1
14	14		F	P	P*		С	P	P	
15	15		K	G	G*	G	s	G	<u>G</u>	
16	16		G	G	G		S	G	G	
17	17		S	S	S*		С	S	S	
18	18		L	M*	· L*		С	L	L	
19	19		K	K*	R	R	С	<u>R</u>	R	
20	20	Ĺ	L	Е	L		С	L	L	
21	21		S	S	S*		С	S	S	
22	22		L	С	C*		С	G	С	
23	23		A	V	A		С	Α	Α	
24	24		'A	Α	Α		С	Α	Α	
25	25		S	S	S*		С	S	S	
26	26		G	G	G		С	G	G	
27	27		F	F	F*		C	F	E	ļ <u>.</u>
28 -	28	•	S	T*	Т	Т	С	T	S	Δ1
29	29		F	F*	F		С	F	F	
30	30	FRI	N	S	S	S	S	S	N	Δ2
31	31	CDR1	· A	N	S	N	С	A	A	
32	32		Y	Y	Y	Α	S	Y_	Y	
33	33		Α	T	Α	W	S	A	Α	
34	34		M	M	М		С	M	M	
35	35		N	N	S	S	С	N	N	
35a			-	-	-		С		-	
35b		CDR1	-	-	-		С	-	-	

Figure 20A

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surf- ace Or Core	1D9 RH _A	1D9 RH _B	Comment
36	36	FR2	W	w	w*		С	w	w	
37	37		V	V	V*	~ *	c	V	V	
38	38	1 1 1	R	R	R*		C	R	R	
39	39		Q	Q	Q*		С	Q	Q	
48	40		A	Š	À		С	A	À	
41	41		P	P	P		S	P	P	
42	42		G	Е	G*		S	G	G	
43	43		K	K	K		S	K	K	
44	44		G	G	G		С	G	G	
45	45		L	L	L*		C	L	L	
46	46		Е	E*	E		С	E	Е	
47	47		W	W	W*		С	W	W	
48	48		V	V*	V*		C	V	V	
49	49	FR2	Α	Α	S	G	C	<u>G</u>	<u>G</u>	
50	50	CDR2	R	Е	V		С	R	R	
51	51		I	I	I		С	I	I	
52	52		R	R	S	K	S	R	R	
52a	53		I	L	G	S	S	T	T	
52b	54		K	K	K*		s	K	K	
52c	55		N	S	T	Т	С	N	N	
53	56	ļlļ	N	Н	D	D		N	N	
54	57		N	N	G	G		N	N	
55	58		<u>Y</u>	· Y	G	G		Y	Y	
56	59		A	A	S	T	S	A	A	
57	60		T	T	T		С	T	Т	
58	61		Y	H	Y	D	С	Y	Y	
59	62	 	Y	Y	Y		С	Y	Y	
60	63		A	A	A		С	A	A	
61	64		D S	E S	S	A P	S	D S	S	
62 63	66			V V	A* .	P	S	V	V	
64	67		- V	K	K		c s	K	K	
65	68	CDR2	R.	G	G*	G	S	D	D	
66	69	FR3	R	R	R*		C	R	R	
67	70	1 1	Y	F	F*	F	C	F	F	
68	71	 	T	T	T	<u> </u>	C	T	T	
69	72	 	i	<u> </u> *	I*		Č	i	I	
70	73		S	S	S*		S	S	s	
71	74		R	R	R*		c	R	R	
72	75		D	D	D		c	D	D	
73	76		D	D	N		C	D	D	
74	77		S	S	.S		S	S	S	1
75	78		Е	K	K	K	S	K	<u>K</u> ·	
76	79		S	S	N	N	S	N	N	
77	80		M	S	T	T	С	Ţ	T	
78	81	1 1	L	V	L		C	L	L	i
79	82		F	Y	Y	Y	С	Y	Y	
80	83	1 1	L	L	L*	· ·	С	L	L	1

Figure 20B

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core	1D9 RH _A	1D9 RH _B	Comment
81	84		Q	_Q*_	Q		С	l Q	Q	
82	85		M	M	M*		С	M	M	
82a	86	i	N	N	N		s	N	N	
82b	87		N	N	S	S	S	<u>s</u>	<u>S</u>	
82c	88		L	L	L*		С	L	L	
83	89		K	R	R		S	K	K	
84	90		T	Α	Α		С	Т	T	
85	91		E	Е	E		S	Е	E	
86	92		D	D	D		C	D	D	
87	93		Т	T	T		С	T	T	
88	94		Α	G	A*		С	A	A	
89	95		M	T	V	V	С	V	V	
90	96		Y	Y	Y*		С	Y	Y	
91	97		Y	Y	Y*		С	Y	Y	
92	98		С	C*	C*		С	G	С	
93	99		V	T	A	T	С	I	<u>T</u>	
94	100	FR3	Т	T	R		С	T	T	<u> </u>
95	101	CDR3	F	G	G	D	С	F	F	
96	102		Y	F	R	S	С	Y	Y	
97	103		G	-	х	L	S	G	G	
98	104		N		G	P	С	N	N	
99			-		х	P	С	•	<u> </u>	
100			-	-	S	H	С	-	-	
100 a			-	-	L		С			
100 d			 -	-	S		С		-	
100 c			-	-	G				-	·
100 d			•	-	х					
100 e			-	-	Y			-	-	
100 f			-	-	Y			-	-	
100 g			-	-	Y			-	-	
100 h			-	-	Y				-	
100 I				_	H				-	
100 ј			•		Y			-	-	
100 k			•	F	F		С	<u></u>	-	
101	105		G	Α	D	P	С	G	G	
102	106	CDR3	V	Y	Y		C	V	V	
103	107	FR4	W	W	W*		С	W	W	
104	108		G	G	G*		С	G	G	
105	109		Т	Q	Q	Q	S	Q	Q	
106	110		G	С	G*		С	G	G	<u> </u>
107	111		T	Т	T*		С	T	T ·	
108	112		T	L	L	L	C	<u>L</u>	<u>L</u>	
109	113		V	V	V*		C	V	V	1
110	114		T	T	T*		С	T	T	ļ
111	115		V	V*	V*			V	V	1
112	116		S	S	S*			S	S	ļ
113	117_	FR4	S	S	S*			S	S	
				1	1		1 1		1	1

Figure 20C

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

100 200 300 400 TICCCAGTAACITIGAGAGTACACGTCGGAGACCTAAGTCGAAGTTACGGATGCGGTACTTGACCCAGGCGGTCCGAGGTCCTTTCCCAAACCTTACCCA TTTCTGCAAATGAACAACTTGAAAACTGAGGACACAGCCATGTATTACTGTGTGACCTTTTACGGTAACGGTGTCTGGGGGCACAGGGACCACGGTCACCG ATGGACTTCGGGTTAAACTIGGTTTTCTTTGTTGTTTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGAGGAGGATTGGTGCAGCCTA TGCTCGCATAAGAACTAAAAATAATTATGCAACATATTATGCCGATTCAGTGAAAGACAGATACACCATCTCCAGAGATGATTCAGAAAGTATGCTC ACGAGCGTATICTIGATITITATTATTAATACGTIGTATAATACGGCTAAGTCACTTTCTGTCTATGTGGTAGAGGTCTCTACTAAGTCTTTCATACGAG TACCTGAAGCCCAATTTGAACCAAAAGAAACAACAAAAAATAGTTCCACACGTAACACTCCACGTCGAACAACTCAGACCTCCTCCTAACCACGTCGGAT AAGGGTCATTGAAACTCTCATGTGCAGCCTCTGGATTCAGCTTCAATGCCTACGCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGT AAAGACGTTTACTTGATTTTGACTCCTGTGTCGGTACATAATGACACACTGGAAAATGCCATTGCCAGAGACCCCGTGTCCCTGGTGCCAGTGGC \mathbf{x} ی ی ۵. ~ S ⋖ s _ 0 variable > 3 <u>~</u> z Σ leader 4 Ø > エ S Ø ی z Υ 0 سا S Ł LL. ⋖ ى S Ø z Þ ں z S S 0

igure 21

ى

ی

z

ی

ں

V

0

لبا

N L K T

z s

0

AGAGGAGTCGGTTTTGTTGTCGGGGTAGGCAGATAGGGGACCA

variable <- The constant

TCTCCTCAGCCAAACAACAGCCCCATCCGTCTATCCCTGGT

22

Figure

GTGGTTGACATAGGTAGAAGGGTGGT

۷

```
00
                                                                                                                                                                     200
                                                                                                                                                                                                                                                                300
                                                                                                                                                                                                                                                                                                                                                         400
                                                                                                                                                                                                                                                                                                                                                                                             constant
                                                                                                                                               ACCCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAGATAGTGATGGAAAGACATTTTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCTCCAAA
                                                                                                                                                                                                                                        GCGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTG
                                                     GAGGCIGAGGATTIGGGAGITIAITATIGCIGGCAAGGIACACATTIICCGIACACGIICGGAGGGGGGGACCAAGCIGGAAATAAAACGGGCIGAIGCIG
                                                                                                                                                                        TGGGTCGGAGGTAGAGAACGTTCAGTTCAGTCTCGGAGAATCTATCACTACCTTTCTGTAAAAACTTAACCAACAATGTCTCCGGTCCGGTCAGAGGTTT
                                                                                                                                                                                                                                                                  CGCGGATTAGATAGACCACAGATITGACCTGAGACCTCAGGGACTGTCCAAGTGACCGTCACCTAGTCCCTGTCTAAAGTGTGACTITTAGTCGTCTCAC
                                                                                                                                                                                                                                                                                                                                                          CICCGACICCTAAACCCICAAAIAATAACGACCGTICCATGIGIAAAAGGCAIGIGCAAGCCIICCCCCIGGIICGACCITIAIIIIGCCCGACTACGAC
                                                                                                                                                                                                                                                                                                                   œ
                                                                                                                                                                                                                        ഗ
                                                                                                                                                                                                                                                                                                                                                                                                            œ
                                                                                                                                                                                                                       ۵
                                                                                                                                                                                                                                                                                                                                                                                          variable
                                                                                                                                                                                                                       o
                                                                                                                                                                                                                                                                                                                3
                                                                                                                                                                                                                                                                                                                ی
                                                                                                                                                                                                                                                                                                                                                                                                          ی
                                                                                                                                                                                                                      z
                                                                                                                        V W T
                                                                                                                                                                                                                                                                                                                                                                                                          ی
                                                                                                                                                                                                                     _
                                                                                                         variable
                                                                                                                                                                                                                                                                                                                                                                                                         ල
                                                                                                                                                                                                                   ட
                                                                                                                                                                                                                                                                                                               S
                                                                                                                                                                                                                     <u>-</u>
                                                                                                                                                                                                                   ×
                                                                                                                        0 9
                                                                                                                                                                                                                   G
                                                                                                                                                                                                                   0
                                                                                                                                                                                                                                                                                                             ~
                                                                                                                      т.
Н
                                                                                                                                                                                                                   S
                                                                                                      leader
                                                                                                                                                                                                                   0
                                                                                                                                                                                                                                                                                                            >
                                                                                                                                                                                                                   _
                                                                                                                                                                                                                                                                                                           ى
                                                                                                                                                                                                                                                                                                           တ
                                                                                                                                                                                                                  0
                                                                                                                                                                                                                                                                                                           ဟ
                                                                                                                                                                                                                                                                                                                                                                                                                            CACCAACTGTATCCATCTTCCCACCA
                                                                                                                                                                                                                 တ
                                                                                                                                                                                                                                                                                                           တ
I Iga
                                                                                                                                                                                                                တ
                                                                                                                                                                                                                 a
I
```

1855.1052-029

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al.

Docket No.:

Inventors:

Title: Humanized Anti-CCR2 Antibodies... Gregory J. LaRosa, et al. Inventors: SŌ ÕE <u>Ö</u> 1GAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTTGGCCGCATAAGAACTAAAAAIAATAATTATGCAACATATTATGCCGATTCAGTGAA AGACAGATICACCATCTCCAGAGATGATTCAAAAACACGCTCTATCTGCAAATGAACAGCTTGAAAACTGAGGACACAGCCGTGTATTACTGTACCACC ICTGICTAAGTGGTAGAGGICTCTACTAAGTTTTTTGTGCGAGATAGACGTTTACTTGTCGAACTTTTGACTCCTGTGTCGGCACATAATGACATGGTGG ACTIGACCCAGGCGGICCGAGGICCITICCCAAACCITACCCAACCGGCGIATICITGATTITATTATTACGTIGTATAATACGGCTAAGICACTT **GAGGTGCAATTGĠ**TTGAGTCTGGAGGAGGATTGGTGAAGCCTGGGGGTCATTGAGACTCTCATGTGCAGCCTCTGGATTCACTTTCAGTGCCTACGCCA CTCCACGTTAACCAACTCAGACCTCCTCCTAACCACTTCGGACCCCCCAGTAACTCTGAGAGTACACGTCGGAGACCTAAGTGAAAGTCACGGATGCGGT z z S z ITTTACGGTAACGGTGTCTGGGGCCCAGGGGACCCTGGTCACCGTCAGCTCAGCCAAA AAAATGCCATTGCCACAGACCCCGGTCCCCTGGGACCAGTGGCAGTCGAGTCGGTTT Figure Σ 0 S ~ IqLa 9 ی ی 3 ی 9 œ S 3

z

1855.1052-029

Docket No.:

I 9JM

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

SÕ <u>3</u>0 TCAGCGGCAGTGGATCAGGGACAGATTTCACACTGAAATCAGCAGAGTGGAGGCTGAGGATGTTGGAGTTTATTACTGCTGGCAAGGTACACATTTTCC AGTCGCCGTCACCTAGTCCCTGTCTAAAGTGTGACTTTTAGTCGTCTCACCTCCGACTCCTACAACCTCAAATAATAACGACCGTTCCATGTGTAAAAGG GAIGCAICACTACTGGGICAGAGGIGAGAGGGAACGGGCAATGGGAACCTGTCGGTCGGAGGTAGAGAACGITCAGIICAGICTCGGAGAATCIAICACIA CTACGTAGTGATGACCCAGTCTCCACTCTCCTTGCCCGTTACCCTTGGACAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAGATAGTGAT G ഗ ~ ပ GTACACGTTCGGACAAGGGACCCGACTGGAAATAAAACGTACGG CATGTGCAAGCCTGTTCCCTGGGCTGACCTTTATTTTGCATGCC S O ۵ 0 0 3 ى z S ල S C \succeq


I Ban2

Figure 2

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

Comparison of Humanized 1D9 vs. m1D9



- mus-1D9
- hum-1D9

	hum-1D9	mus-1D9
Equation 1		
Best-fit values		
BOTTOM	23.46	22.40
TOP (Constant)	100.0	100.0
LOGECSO	1.452	1.472
HILLSLOPE	-1.972	-1.627
EC50	28.32	29.68
Std. Error		
BOTTOM	2.656	3.945
LOGEC50	0.04151	0.06251
HILLSLOPE	0.2946	0.3143
95% Confidence Intervals		
BOTTOM	17.18 to 29.74	13.07 to 31.73
LOGEC50	1.354 to 1.550	1.325 to 1.620
HILLSLOPE	-2.668 to -1.275	-2.370 to -0.8835
EC50	22.59 to 35.51	21.12 to 41.71
Goodness of Fit		
Degrees of Freedom	7	7
R squared	0.9931	0.9858
Absolute Sum of Squares	48.60	88.53
Syx	2.635	3.556
Data	1	
Number of X values	10	10
# of Y replicates (mean analyzed)	3	3
Total number of values	10	10
Number of missing values	20	20

Figure 25